e-learning
resources
Virtual 2021
05.09.2021
New insights into the airway immunology of lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
IL-36? – a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease
J. Baker (London, United Kingdom), P. Fenwick (London, United Kingdom), H. Owles (London, United Kingdom), C. Koss (Biberach an der Riß, Germany), K. El-Kasmi (Biberach an der Riß, Germany), P. Barnes (London, United Kingdom), L. Donnelly (London, United Kingdom)
Source:
Virtual Congress 2021 – New insights into the airway immunology of lung disease
Session:
New insights into the airway immunology of lung disease
Session type:
E-poster
Number:
678
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Baker (London, United Kingdom), P. Fenwick (London, United Kingdom), H. Owles (London, United Kingdom), C. Koss (Biberach an der Riß, Germany), K. El-Kasmi (Biberach an der Riß, Germany), P. Barnes (London, United Kingdom), L. Donnelly (London, United Kingdom). IL-36? – a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease. 678
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
A 62-year-old man with scanty mucoid sputum
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: 325-331
Year: 2002
IL-17C associates with disease severity during acute exacerbation of chronic obstructive disease and promotes neutrophilic lung inflammation
Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations
Year: 2019
Suppressed pulmonary expression of leptin in lipopolysaccharide-induced acute and chronic lung inflammation
Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS)
Year: 2006
Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
The role of biomarkers to identify bacterial and eosinophilic airway inflammation in exacerbations of chronic obstructive pulmonary disease
Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring
Year: 2010
Association between airway inflammation and systemic inflammation in stable chronic obstructive pulmonary disease
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Systemic inflammation in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: 5S-13S
Year: 2003
Multiple inflammatory hits and the pathogenesis of severe airway disease
Source: Eur Respir J 2006; 27: 884-888
Year: 2006
Interleukin-18 production and pulmonary function in COPD
Source: Eur Respir J 2008; 31: 287-297
Year: 2008
The role of inflamatory markers in obstructive pulmonary disease
Source: Annual Congress 2012 - Distinguishing phenotypes and dealing with comorbidities in primary care
Year: 2012
Pattern of airway inflammation and remodeling in mild chronic obstructive pulmonary disease
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
The role of inflammation in COPD
Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases
Year: 2006
Systemic effects of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 347-360
Year: 2003
Inflammatory markers in patients with acute exacerbation of chronic obstructive pulmonary disease and role of bacterial infection
Source: Annual Congress 2010 - Colonisation and infection in COPD
Year: 2010
Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 25: 640-646
Year: 2005
Systemic inflammation: a link between chronic obstructive pulmonary disease and lung cancer?
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Autoimmunity, T-cells and STAT-4 in the pathogenesis of chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: 3-5
Year: 2004
Measurements of sputum interleukin-5 in chronic obstructive pulmonary disease patients with eosinophilic airway inflammation
Source: Annual Congress 2008 - Phenotyping of asthma and COPD
Year: 2008
Periostin as a marker of Th2-related inflammation in patients with different types of chronic obstructive airway disease
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017
Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?
Source: Eur Respir J 2002; 20: 9S-19S
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept